Here's Why Unity Biotechnology Is Getting Crushed Today
Shares of Unity Biotechnology (NASDAQ: UBX) fell over 63% today after the company announced disappointing results from a clinical trial involving its lead drug candidate, UBX0101.
At the 12-week mark of a phase 2 study, the pipeline asset failed to meet its primary endpoint in alleviating moderate to severe painful osteoarthritis (OA) of the knee. In fact, there were no statistically significant differences between any dose of UBX0101 and placebo.
As of 1:22 p.m. EDT, the small-cap stock had settled to a 61.3% loss.
Source Fool.com
